📊 QDEL Key Takeaways
Is QuidelOrtho Corp (QDEL) a Good Investment?
QuidelOrtho faces severe financial distress with persistent operating losses (-33.7% margin), negative free cash flow (-$83M), and unsustainable debt burden ($2.7B) relative to weak cash position. Revenue contraction combined with structural unprofitability and deteriorating liquidity (0.90x quick ratio) indicates material solvency risk without substantial operational turnaround or debt restructuring.
Why Buy QuidelOrtho Corp Stock? QDEL Key Strengths
- Positive operating cash flow of $105.2M demonstrates underlying business can generate cash from operations
- Net income loss improved 44.8% YoY showing sequential progress toward profitability
- Reasonable current ratio of 1.50x provides near-term liquidity buffer for operations
QDEL Stock Risks: QuidelOrtho Corp Investment Risks
- Severe operating losses (-$919.2M) and negative net margin (-41.5%) indicate core business model is unprofitable and unsustainable
- Negative free cash flow (-$83M) with capex exceeding operating cash flow signals inability to self-fund growth or service debt
- High leverage (1.40x debt/equity, $2.7B debt vs $169.8M cash) creates refinancing risk and limits financial flexibility
- Revenue declining year-over-year while maintaining negative margins compounds financial deterioration
- Quick ratio of 0.90x below 1.0 signals potential short-term liquidity constraints
Key Metrics to Watch
- Operating margin trajectory toward positive territory
- Free cash flow path to positive cash generation
- Revenue stabilization and organic growth resumption
- Debt reduction progress and refinancing success
- Working capital efficiency and cash conversion cycle improvement
QuidelOrtho Corp (QDEL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
QuidelOrtho Corp presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
QDEL Profit Margin, ROE & Profitability Analysis
QDEL vs Healthcare Sector: How QuidelOrtho Corp Compares
How QuidelOrtho Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is QuidelOrtho Corp Stock Overvalued? QDEL Valuation Analysis 2026
Based on fundamental analysis, QuidelOrtho Corp shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
QuidelOrtho Corp Balance Sheet: QDEL Debt, Cash & Liquidity
QDEL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: QuidelOrtho Corp's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.15 indicates the company is currently unprofitable.
QDEL Revenue Growth, EPS Growth & YoY Performance
QDEL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $699.9M | -$12.7M | $-0.30 |
| Q2 2025 | $613.9M | -$12.7M | $-2.20 |
| Q1 2025 | $692.8M | -$12.7M | $-0.19 |
| Q3 2024 | $727.1M | -$12.7M | $-0.19 |
| Q2 2024 | $637.0M | -$4.4M | $-0.07 |
| Q1 2024 | $711.0M | $48.8M | $0.73 |
| Q3 2023 | $744.0M | -$12.7M | $-0.19 |
| Q2 2023 | $613.4M | -$4.4M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
QuidelOrtho Corp Dividends, Buybacks & Capital Allocation
QDEL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for QuidelOrtho Corp (CIK: 0001906324)
📋 Recent SEC Filings
❓ Frequently Asked Questions about QDEL
What is the AI rating for QDEL?
QuidelOrtho Corp (QDEL) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are QDEL's key strengths?
Claude: Positive operating cash flow of $105.2M demonstrates underlying business can generate cash from operations. Net income loss improved 44.8% YoY showing sequential progress toward profitability.
What are the risks of investing in QDEL?
Claude: Severe operating losses (-$919.2M) and negative net margin (-41.5%) indicate core business model is unprofitable and unsustainable. Negative free cash flow (-$83M) with capex exceeding operating cash flow signals inability to self-fund growth or service debt.
What is QDEL's revenue and growth?
QuidelOrtho Corp reported revenue of $2.7B.
Does QDEL pay dividends?
QuidelOrtho Corp does not currently pay dividends.
Where can I find QDEL SEC filings?
Official SEC filings for QuidelOrtho Corp (CIK: 0001906324) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is QDEL's EPS?
QuidelOrtho Corp has a diluted EPS of $-16.69.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is QDEL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, QuidelOrtho Corp has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is QDEL stock overvalued or undervalued?
Valuation metrics for QDEL: ROE of -58.9% (sector avg: 15%), net margin of -41.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy QDEL stock in 2026?
Our dual AI analysis gives QuidelOrtho Corp a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is QDEL's free cash flow?
QuidelOrtho Corp's operating cash flow is $105.2M, with capital expenditures of $188.2M. FCF margin is -3.0%.
How does QDEL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -41.5% (avg: 12%), ROE -58.9% (avg: 15%), current ratio 1.50 (avg: 2).